HCB101 does not target CD16B. It binds CD47 on tumor cells to block the CD47–SIRPα checkpoint and, via its IgG4 Fc, engages Fcγ receptors (including CD16B) on myeloid cells to enhance phagocytic/effector activity against CD47+ tumor cells; CD16B+ cells act as effectors, not targets.